Phase 2
N=10
Glyburide Advantage in Malignant Edema and Stroke Pilot
Ischemic Stroke
Bottom Line
View on ClinicalTrials.gov: NCT01268683 ↗Enrolled (actual)
10
Serious AEs
30.0%
Results posted
Jun 2014
Primary outcome: Primary: Rate of Enrollment — 9.6 Months
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Glyburide for Injection (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Remedy Pharmaceuticals, Inc.
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Enrollment |
9.6 | — |
| PRIMARY Percentage of Enrolled Participants to Screened Participants |
5.7 | — |
| PRIMARY Percentage of Participants Completing 90-Day Follow-Up |
80 | — |
| PRIMARY Percentage of Dose Reductions/ Dose Suspensions |
— | — |
| PRIMARY Percentage of Participants With All Four MRI Assessments Per Protocol |
90 | — |
| PRIMARY Number of MRI Assessments Per Participant |
3.9 | — |
| PRIMARY Percentage of Participants Requiring One or More Hypoglycemia Treatments |
— | — |
| PRIMARY Percentage of Participants With Pre-specified Adverse Events Associated With Glyburide According to Protocol |
— | — |
| SECONDARY Number of Participants With Adverse Events and Serious Adverse Events |
10; 3 | — |
| SECONDARY Infarcted Hemisphere Volume |
135.20; 156.78; 165.38; 181.71 | — |
| SECONDARY Absolute Diffusion Weighted Imaging (DWI) Lesion Volume |
101.76; 141.62; 152.31; 169.73 | — |
| SECONDARY Change From Baseline in DWI Lesion Volume |
60.30 | — |
| SECONDARY Midline Shift |
0.56; 2.00; 2.63; 2.50 | — |
| SECONDARY Ipsilateral Ventricle Volume |
11.78; 9.25; 8.92; 10.07 | — |
| SECONDARY Frequency of Hemorrhagic Events |
3; 8; 0; 0 | — |
| SECONDARY National Institute of Health Stroke Scale (NIHSS) Score |
17.8; 18.4; 15.6; 16.2; 13.9 | — |
| SECONDARY Glasgow Coma Scale (GCS) Score |
12.5; 11.9; 12.5; 12.8; 13.5 | — |
| SECONDARY Full Outline of UnResponsiveness (FOUR) Score |
15.1; 14.5; 14.6; 14.6; 14.8 | — |
| SECONDARY Number of Participants Requiring Decompressive Craniectomy (DC) |
2 | — |
| SECONDARY Number of Participants With a Modified Rankin Scale (mRS) Score ≤ 4 |
9; 8 | — |
Summary
The primary objective of this study is to assess the feasibility of enrolling, evaluating, and treating with glyburide for injection severe anterior circulation ischemic stroke participants, whether or not treated with standard of care intravenous (IV) recombinant tissue plasminogen activator (rtPA). Participants must be between 18-80 years of age, must have a baseline diffusion weighted image (DWI) lesion volume 82 -210 centimeters cubed (cm3), and time from symptom onset to start of study infusion must be ≤10 hour(hr). The secondary objectives are to assess the initial safety and tolerability, and pharmacokinetics (PK) /pharmacodynamics (PD) of glyburide in severe stroke participants, as well as to compare the clinical and magnetic resonance imaging (MRI) outcome data to benchmark data derived from published literature.
Eligibility Criteria
Key Inclusion Criteria
- A clinical diagnosis of acute ischemic stroke in the MCA or MCA/ACA territory.
- Pre-morbid mRS 0 - 1.
- A baseline DWI lesion between 82 cm3 and 210 cm3 on MRI.
- Patients treated with IV rtPA should meet established criteria for IV rtPA administration in the 0-3 and 3-4.5 hr time periods, respectively.
- The time to the start of infusion of study compound must be ≤ 10 hr after time of symptom onset
- Age ≥18 years and ≤70 years.
- Provision of written informed consent by the patient or from a legally authorized representative according to institutional guidelines and national regulations.
Key Exclusion Criteria
- Evidence from imaging or pre-enrollment investigation of any diagnosis other than acute ischemic stroke likely to cause the presenting symptoms and signs.
- Commitment to decompressive craniectomy (DC) prior to enrollment, or follow-ing enrollment and prior to start of study compound.
- Treatment with IA rtPA or by mechanical means for clot disruption or with hypo-thermia.
- Patients unable to tolerate MRI scanning, e.g. those with pacemakers or automatic defibrillators.
- Pre-morbid mRS ≥ 2.
- Clinical signs of herniation, e.g. one or two dilated, fixed pupils; unconsciousness (i.e., ≥ 2 on item 1a on the NIHSS); loss of other brain stem reflexes attributable to herniation according to the investigator's judgment.
- CT or MRI evidence of hemorrhage or anteroseptal/pineal shift greater ≥2 mm prior to enrollment.
- Rapidly improving symptoms.
- Severe renal disorder from the patient's history (e.g. dialysis) or eGFR of 2 times normal.
- Blood glucose 20, etc.)
- Sulfonylurea treatment within 30 days.
- Known allergy to sulfa or specific allergy to sulfonylurea drugs.
- Known G6PD enzyme deficiency.
- Pregnancy or breast-feeding. Women must be either post-menopausal (judged by the investigator), permanently sterilized or, if of childbearing age, must have a negative test for pregnancy obtained before enrollment.
- Patients already enrolled in a non-observation-only stroke study, or with life-expectancy <3 months not related to current stroke, or those unlikely to be com-pliant with follow up.
- Patients who, in the opinion of the investigator, are not suitable for the study (reason to be documented).
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Data sourced from ClinicalTrials.gov (NCT01268683). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.